When United States officials briefly paused the use of Johnson & Johnson’s coronavirus vaccine Tuesday to warn victims and providers of a “remarkably rare” blood clotting problem that has so far affected just six of the millions of Americans who have got the vaccine six of them women ages between 18 to 48. There were several members worried the sudden move would halt a substantial number of Americans from getting shot.
But if we take a nearer look at the information, it is certain that unless governors settle up pulling J&J from the market result experts have all but ruled out, given the vaccine’s robust track record of security and effectiveness and the minuscule risk of clotting this week’s time-out may have an impact on the larger dynamics of America’s vaccination campaign.
Because before the J&J news, the United States was addressing a vaccine wall already at the point at which supply outstrips demand, the country’s rapid pace of vaccination begins to drop down and all those American who wants to get vaccine can get whatever shot they want, whether it’s Moderna, Pfizer, or the J&J.
By all means, the United States has made striking progress on vaccination. When Biden President took office on the 20th of January, the country was serving for about 900,000 shots per day. Less than three months later now, the pace has almost quadrupled to 3.4M daily doses. On Saturday, 4.6M shots were reported a new record. More than 63% of U.S. superiors have been completely vaccinated, up from 2% at the beginning of Biden’s term; almost half of U.S. adults have received at least one jab. And that’s exactly before eligibility has opened up to all greater than 16 years or older, a threshold the country is set to cross on the 19th of April officially.
Stay tuned for more updates!!